EuroFlow™ Databases for Plasma cell dyscrasias

The number of immunophenotypic markers that can be evaluated in 8-color assays and the high number of cells interrogated using the MM MRD and CTPC methodology increase the complexity of data analysis. EuroFlow™ developed and validated two reference databases, one for monitoring of circulating tumor plasma cells (CTPC) in peripheral blood at diagnosis and during/post-treatment and another database for MRD assessment in bone marrow samples after treatment. The databases should only be used with files which follow the EuroFlow™ standardized operating procedures.

How were the CTPC and MM MRD databases built?

CTPC Database
EuroFlow™ developed and validated a database containing representative peripheral blood samples from normal/healthy donors and abnormal CTPC from patient samples stained with the CTPC panel and processed in a standardized manner following EuroFlow™ SOPs.

MM MRD Database
EuroFlow™ developed and validated a database containing representative bone marrow samples from normal/healthy donors stained with the MM MRD panel following EuroFlow™ SOPs.

In both, CTPC and MM MRD Databases, the samples were collected in different EuroFlow™ centers to reflect biological and technical variability regarding different laboratories, instruments and operators. EuroFlow™ experts analyzed those samples and created a library of reference populations. When comparing a new sample with this database, all populations of the sample will be automatically identified.

How to compare a new case with EuroFlow™ MM MRD Database using Infinicyt™ Automated Gating & Identification tool?

  1. Compatible FCS file
    Acquired using the EuroFlow™ SOPs for instrument set-up, sample preparation and antibody panel.
  2. Clustering
    All events are automatically identified by clustering algorithms.
  3. Identification with EuroFlow Databases
    Infinicyt™ automatically compares the clusters with EuroFlow™ Database:
    – Clusters identical to cell populations included in the database are directly renamed with the name of those populations.
    – Clusters that are not identical to the ones included in the database are assigned to Check Populations. The user has to review them and decide whether they are normal or abnormal.
  4. Automatic Report includes:
    – Frequency of each population with reference ranges.
    – Relevant information for clinical routine automatically updated for each sample.
    – Available in 13 different languages.
    Click to see and example of CTPC Report and MM MRD Report.

Resources

Publications:

  1. Flores-Montero, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. Go to publication.
  2. Sanoja-Flores L, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019 Oct; 8(12):epub. Go to publication.
  3. Flores-Montero J, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017 Oct;31(10):2094-103. Go to publication.
  4. Sanoja-Flores L, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018 Nov;8(12):117. Go to publication.
  5. Sanoja-Flores L, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019 Oct; 8(12):epub. Go to publication.